Edison Initiates Coverage on Probiodrug

LONDON, June 1, 2015 /PRNewswire/ --

Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage of Probiodrug 

Highlights of the analysis of Probiodrug by Edison's healthcare analysts Dr Lucy Codrington, Dr Philippa Gardner and Christian Glennie include:

     (Logo: http://photos.prnewswire.com/prnh/20130417/608168 )

Probiodrug is a pure-play Alzheimer's disease (AD) company, developing a clinical pipeline that focuses on a novel, earlier-stage target, pGlu-Abeta, which could allow successful development of a disease-modifying therapy for AD. Recruitment to the Phase IIa study of oral PQ912 has commenced with first data expected in mid-2016. Current cash should provide sufficient funding until data readout, when Probiodrug will likely seek to partner PQ912. We value Probiodrug at €216m or €31.9/share.

Probiodrug is a German biopharmaceutical company developing its clinical pipeline for the treatment of Alzheimer's disease. Lead product candidate, PQ912, has entered Phase IIa; two further products are in preclinical stages.

To download this report, please click here.

All reports published by Edison are available to download free of charge from its website http://www.edisongroup.com.

About Edison: Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support their capital markets activities. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:  

LinkedIn http://www.linkedin.com/company/edison-investment-research
Twitter http://www.twitter.com/Edison_Inv_Res
YouTube http://www.youtube.com/edisonitv 

For more information please contact:
Dr Lucy Codrington
Edison Investment Research    
+44-(0)20-3681-2527

Dr Philippa Gardner
Edison Investment Research
+44-(0)20-3681-2521

Christian Glennie
Edison Investment Research    
+44-(0)20-3077-5727
[email protected]

SOURCE Edison Investment Research

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED